Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trasylol prompts Bayer study review changes

Executive Summary

Firm is amending its process for reviewing drug studies in light of conclusions by an independent reviewer that its current procedures were partly to blame for Bayer's failure to disclose Trasylol data to FDA prior to a September 2006 advisory committee meeting. Bayer's Protocol Review Committee oversight will be extended to company-sponsored or co-development studies in six categories, including pharmacoepidemiological studies such as the i3 Drug Safety study of Trasylol, company says in an Aug. 17 press release. Bayer came under fire last year when it was revealed two employees knew of preliminary results of the i3 study but did not disclose them before the agency's Cardiovascular and Renal Drugs Advisory Committee meeting, which was convened to review Trasylol's safety. Overall, the report by William Taylor, a partner with Zuckerman Spaeder, exonerates Bayer staff and blames the issue on operational factors and "human error"...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS048705

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel